Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Fair Pricing Coalition Urges a Uniform Price for Curative Hepatitis C Treatment

The $63,000 wholesale acquisition cost (WAC) for eight weeks of Harvoni™ (sofosbuvir and ledipasvir) should be extended to 12 and 24-week curative treatment durations.

Published
15 October 2014
From
Fair Pricing Coalition
If AbbVie Discounts its Hep C Drug, Would Pricing Reach a Tipping Point?

Now that the FDA has approved the Harvoni treatment from Gilead Sciences and a $94,500 price for a 12-week regimen has been established, attention is turning toward AbbVie and the steps the big drug maker must take to win market share. Already, though, some Wall Street prognosticators believe AbbVie may find it daunting.

Published
15 October 2014
From
Wall Street Journal
HCV core-antigen testing is a reliable way of detecting acute HCV infections in HIV-positive gay men

Hepatitis C virus (HCV) core-antigen testing is a highly reliable way of diagnosing acute HCV infections in people living with HIV, investigators from the United Kingdom report

Published
13 October 2014
By
Michael Carter
As Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles

As Gilead Sciences launches its next generation Hepatitis C pill, Harvoni, Medicaid programs are bracing for another extraordinary wave of costs, with 70 percent of states implementing coverage restrictions.

Published
10 October 2014
From
Forbes
U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

Harvoni’s efficacy has been established in patients with chronic hepatitis C virus (HCV) genotype 1 infection, with a treatment duration of eight, 12 or 24 weeks depending on prior treatment history, cirrhosis status and baseline viral load. Eight weeks of treatment with Harvoni can be considered for treatment-naïve patients without cirrhosis who have baseline HCV viral load below 6 million IU/mL.

Published
10 October 2014
From
Gilead press release
Thousands of Hep C patients in Alexandria wait in long lines to receive Sovaldi

Thousands of Hepatitis C virus patients have flooded two medical centers in Alexandria in hopes of receiving the new Hep C Sovaldi drug, after the health ministry said it will be providing it for patients.

Published
10 October 2014
From
Egypt Independent
Sovaldi ‘unaffordable’ says NHS documents

Senior health officials may have to bar Gilead’s new hepatitis C pill Sovaldi from being funded on the NHS after new data shows it would cost the health service £1 billion a year to fund.

Published
08 October 2014
From
Pharmafile
In a surprise move, Bristol-Myers drops U.S. approval plans for hep C drug

After sizing up the competitive landscape as rival Gilead ($GILD) races ahead with a new combo treatment, Bristol-Myers has opted to drop its application to gain an approval in the U.S. for asunaprevir, its NS3/4A protease inhibitor, and won't go after an OK to use a combination of daclatasvir and asunaprevir for genotype 1b patients.

Published
07 October 2014
From
Fierce Biotech
CVS: One In 12 Hepatitis C Patients Not Adhering To $1,000/Day Pill

Over 8 percent of hepatitis C patients taking Sovaldi (sofosbuvir; Gilead) are failing to complete their full, 12-week course of drug therapy, a dropout rate roughly four times that observed in clinical trials. By discontinuing the drug, shown to have a 90+% cure rate, these patients (and their insurance providers) are incurring health care costs of $28,000 or $56,000, without knowing if they are rid of the virus.

Published
07 October 2014
From
Forbes
Most Spanish patients coinfected with HIV/HCV called difficult to cure

Most patients coinfected with HIV and hepatitis C virus infection at a clinic in Spain were considered “difficult to cure” primarily because of their HCV genotype and other factors, according to data presented at the AASLD/EASL Special Conference on Hepatitis C.

Published
07 October 2014
From
Healio

Filter by country